JP2014523521A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523521A5
JP2014523521A5 JP2014513770A JP2014513770A JP2014523521A5 JP 2014523521 A5 JP2014523521 A5 JP 2014523521A5 JP 2014513770 A JP2014513770 A JP 2014513770A JP 2014513770 A JP2014513770 A JP 2014513770A JP 2014523521 A5 JP2014523521 A5 JP 2014523521A5
Authority
JP
Japan
Prior art keywords
loxl2
disease
antibody
level
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014513770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/040585 external-priority patent/WO2012167181A1/en
Publication of JP2014523521A publication Critical patent/JP2014523521A/ja
Publication of JP2014523521A5 publication Critical patent/JP2014523521A5/ja
Withdrawn legal-status Critical Current

Links

JP2014513770A 2011-06-01 2012-06-01 リシルオキシダーゼ様2のアッセイおよびその使用の方法 Withdrawn JP2014523521A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161492210P 2011-06-01 2011-06-01
US61/492,210 2011-06-01
US201161550895P 2011-10-24 2011-10-24
US61/550,895 2011-10-24
US201161578813P 2011-12-21 2011-12-21
US61/578,813 2011-12-21
PCT/US2012/040585 WO2012167181A1 (en) 2011-06-01 2012-06-01 Lysyl oxidase-like 2 assay and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016115175A Division JP2016164578A (ja) 2011-06-01 2016-06-09 リシルオキシダーゼ様2のアッセイおよびその使用の方法

Publications (2)

Publication Number Publication Date
JP2014523521A JP2014523521A (ja) 2014-09-11
JP2014523521A5 true JP2014523521A5 (cg-RX-API-DMAC7.html) 2015-06-18

Family

ID=46208194

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014513770A Withdrawn JP2014523521A (ja) 2011-06-01 2012-06-01 リシルオキシダーゼ様2のアッセイおよびその使用の方法
JP2016115175A Pending JP2016164578A (ja) 2011-06-01 2016-06-09 リシルオキシダーゼ様2のアッセイおよびその使用の方法
JP2017221000A Pending JP2018049033A (ja) 2011-06-01 2017-11-16 リシルオキシダーゼ様2のアッセイおよびその使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016115175A Pending JP2016164578A (ja) 2011-06-01 2016-06-09 リシルオキシダーゼ様2のアッセイおよびその使用の方法
JP2017221000A Pending JP2018049033A (ja) 2011-06-01 2017-11-16 リシルオキシダーゼ様2のアッセイおよびその使用の方法

Country Status (25)

Country Link
US (3) US20120309020A1 (cg-RX-API-DMAC7.html)
EP (1) EP2714744A1 (cg-RX-API-DMAC7.html)
JP (3) JP2014523521A (cg-RX-API-DMAC7.html)
KR (1) KR20140048156A (cg-RX-API-DMAC7.html)
CN (1) CN103946241A (cg-RX-API-DMAC7.html)
AP (1) AP2013007285A0 (cg-RX-API-DMAC7.html)
AR (1) AR086657A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012261883A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013030682A2 (cg-RX-API-DMAC7.html)
CA (1) CA2837534A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013003445A1 (cg-RX-API-DMAC7.html)
CO (1) CO6940375A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130657A (cg-RX-API-DMAC7.html)
EA (1) EA201391627A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013092A (cg-RX-API-DMAC7.html)
IL (1) IL229631A0 (cg-RX-API-DMAC7.html)
MA (1) MA35212B1 (cg-RX-API-DMAC7.html)
MD (1) MD20130098A2 (cg-RX-API-DMAC7.html)
MX (1) MX2013013905A (cg-RX-API-DMAC7.html)
PE (1) PE20141450A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502490A1 (cg-RX-API-DMAC7.html)
TW (1) TW201319572A (cg-RX-API-DMAC7.html)
UY (1) UY34115A (cg-RX-API-DMAC7.html)
WO (1) WO2012167181A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201308812B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2009035791A1 (en) 2007-08-02 2009-03-19 Arresto Biosciences Lox and l0xl2 inhibitors and uses thereof
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
JP2013502226A (ja) 2009-08-21 2013-01-24 ギリアド バイオロジクス,インク. リシル酸化酵素及びloxl2由来の触媒ドメイン
KR20130008021A (ko) * 2010-02-04 2013-01-21 길리아드 바이오로직스, 인크. 리실 산화효소-유사 2 (loxl2)에 결합하는 항체, 및 그를 위한 사용 방법
JP2016500700A (ja) * 2012-10-30 2016-01-14 ギリアード サイエンシーズ, インコーポレイテッド リシルオキシダーゼ様2(loxl2)に関する治療および診断方法
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
CN106456772A (zh) 2014-06-11 2017-02-22 吉利德科学公司 用于治疗心血管疾病的方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
EP3423057A1 (en) 2016-03-04 2019-01-09 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
GB201704206D0 (en) * 2017-03-16 2017-05-03 Nordic Bioscience As Lysyl oxidase like-2 assay
US20230152330A1 (en) * 2021-11-17 2023-05-18 AmMax Bio, Inc. Detection and treatment of idiopathic pulmonary fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352862B1 (en) * 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
FI92882C (fi) * 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2009035791A1 (en) 2007-08-02 2009-03-19 Arresto Biosciences Lox and l0xl2 inhibitors and uses thereof
JP2010038735A (ja) * 2008-08-05 2010-02-18 Terumo Corp 腹膜機能の評価方法および腹膜機能評価用イムノクロマト試験紙
CA2771778A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. Methods and compositions for treatment of pulmonary fibrotic disorders
KR20130008021A (ko) * 2010-02-04 2013-01-21 길리아드 바이오로직스, 인크. 리실 산화효소-유사 2 (loxl2)에 결합하는 항체, 및 그를 위한 사용 방법
CN103492688B (zh) * 2011-05-10 2016-02-10 博格华纳公司 具有可变涡轮几何形状的涡轮增压器

Similar Documents

Publication Publication Date Title
JP2014523521A5 (cg-RX-API-DMAC7.html)
Koch et al. Nanopore sequencing of DNA-barcoded probes for highly multiplexed detection of microRNA, proteins and small biomarkers
McGill et al. Serum mitochondrial biomarkers and damage‐associated molecular patterns are higher in acetaminophen overdose patients with poor outcome
Darmanis et al. Sensitive plasma protein analysis by microparticle-based proximity ligation assays
Mukherjee et al. Diagnosis and management of hepatitis C virus infection
JP2016538545A5 (cg-RX-API-DMAC7.html)
Roux et al. Characteristics of donor-specific antibodies associated with antibody-mediated rejection in lung transplantation
WO2006126008A3 (en) Improved immunoassay methods
JP2018049033A (ja) リシルオキシダーゼ様2のアッセイおよびその使用の方法
Schenz et al. Molecular and biomarker-based diagnostics in early sepsis: current challenges and future perspectives
Lin et al. Plasma protein biosignatures for detection of cardiac allograft vasculopathy
Panteghini et al. Total error vs. measurement uncertainty: the match continues
Morio et al. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury
Erek-Toprak et al. Association of plasma growth arrest-specific protein 6 (Gas6) concentrations with albuminuria in patients with type 2 diabetes
Kaur et al. Defining target product profiles (TPPs) for aptamer-based diagnostics
Thrailkill et al. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens
JP4272066B2 (ja) Ca19−9の測定による敗血症の検出方法
Enomoto et al. An increased ratio of glycated albumin to HbA1c is associated with the degree of liver fibrosis in hepatitis B virus‐positive patients
Cut et al. Autopsy Findings and Inflammatory Markers in SARS-CoV-2: A Single-Center Experience
Nomikou et al. Soluble CD146, a novel endothelial marker, is related to the severity of liver disease
US20250130237A1 (en) Point of Care Assays
Kwon et al. Rapid determination of blood coagulation factor XIII activity using protein arrays for serodiagnosis of human plasma
JP2009517381A5 (cg-RX-API-DMAC7.html)
Ranjitkar et al. Susceptibility of commonly used ferritin assays to the classic hook effect
CN102971630A (zh) 非酒精性脂肪性肝炎检测和/或鉴别用标记物、检测和/或鉴别非酒精性脂肪性肝炎的方法及用于它们的试剂盒